In summary, long-acting GIPR agonists have been shown to decrease body weight and to improve glucose handling in a series of preclinical studies184,185 and a long-acting GIPR agonist is in phase I clinical trials for the treatment of T2D (Table 2) (see Related links). The gene discussed is GIPR; the disease is type 2 diabetes mellitus.